Olema Pharmaceuticals (OLMA) Other Accumulated Expenses (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Other Accumulated Expenses data on file, last reported at $35.4 million in Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $35.4 million, up 42.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $35.4 million (up 42.22% YoY), and the FY2025 annual result was $41.4 million, up 14.67% from the prior year.
• Other Accumulated Expenses fell to $35.4 million in Q1 2026 per OLMA's latest filing, from $41.4 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $41.4 million in Q4 2025 and troughed at $4.9 million in Q1 2022.
• A 5-year average of $19.8 million and a median of $15.2 million in 2022 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2023: Other Accumulated Expenses surged 17127.27% in 2022, then decreased 26.93% in 2023.
• A 5-year view of Other Accumulated Expenses shows it stood at $15.2 million in 2022, then dropped by 25.32% to $11.3 million in 2023, then jumped by 219.08% to $36.1 million in 2024, then increased by 14.67% to $41.4 million in 2025, then dropped by 14.55% to $35.4 million in 2026.
• Business Quant data shows OLMA's Other Accumulated Expenses at $35.4 million in Q1 2026, $41.4 million in Q4 2025, and $29.7 million in Q3 2025.